New Gene Editing Stock [Should We Buy?]
Gene editing investors may soon have one more stock to choose from. A gene-editing company called Metagenomi $MGX uses AI to discover novel CRISPR gene editing methods from nature and they're planning to have an IPO. We start by looking at all the current players according to the IPO S-1 filing, then describe what the ideal gene editing business model looks like. Then, we describe how MGX plans to compete against CRISPR CAS9 competitors like CRISPR Therapeutics and Intellia Therapeutics. Basically, they have better technology - a platform that uses AI to discover gene editing tools - and they…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.